{
  "thread": {
    "uuid": "528e02917360f9e73166e60d90ef145359ed8a47",
    "url": "https://www.wallstreet-online.de/nachricht/19567010-novartis-provides-update-on-phase-iii-gcaptain-study-of-cosentyx-giant-cell-arteritis-gca",
    "site_full": "www.wallstreet-online.de",
    "site": "wallstreet-online.de",
    "site_section": "https://www.wallstreet-online.de/nachrichten/aktien-indizes",
    "site_categories": [
      "investing",
      "tennis",
      "finance",
      "sports"
    ],
    "section_title": "Aktien & Indizes Nachrichten und Informationen",
    "site_title": "Aktien - Börse - Aktienkurse",
    "title": "Novartis provides update on Phase III GCAptAIN study of Cosentyx in giant cell arteritis (GCA) - 03.07.2025",
    "title_full": "Novartis provides update on Phase III GCAptAIN study of Cosentyx in giant cell arteritis (GCA) - 03.07.2025",
    "published": "2025-07-03T08:15:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "DE",
    "main_image": "https://assets.wallstreet-online.de/_media/6/source1280/size_645/globenewswire-1280.png",
    "performance_score": 0,
    "domain_rank": 17005,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "528e02917360f9e73166e60d90ef145359ed8a47",
  "url": "https://www.wallstreet-online.de/nachricht/19567010-novartis-provides-update-on-phase-iii-gcaptain-study-of-cosentyx-giant-cell-arteritis-gca",
  "ord_in_thread": 0,
  "author": "globenewswire",
  "published": "2025-07-03T08:15:00.000+03:00",
  "title": "Novartis provides update on Phase III GCAptAIN study of Cosentyx in giant cell arteritis (GCA) - 03.07.2025",
  "text": "The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA 1\nSafety in GCA patients was consistent with known safety profile of Cosentyx (secukinumab) 1\nBasel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).\nIn the study, Cosentyx was evaluated in combination with a 26-week steroid taper and compared to placebo plus a 52-week steroid taper. Cosentyx did not demonstrate a statistically significant improvement in sustained remission at Week 52 compared to placebo. While the secondary outcomes did not show statistical superiority, Cosentyx showed numerically better outcomes compared to placebo for cumulative steroid dose and steroid-related toxicity 1 . Safety in GCA was consistent with the known safety profile of Cosentyx 1 , which is supported by robust evidence and 10 years of real-world data across its approved indications 2- 7 .\nAnzeige Handeln Sie Ihre Einschätzung zu Novartis AG! Long 91,13€ Basispreis 0,79 Ask × 13,28 Hebel Zum Produkt Short 106,35€ Basispreis 0,90 Ask × 11,67 Hebel Zum Produkt Präsentiert von Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.\n“While the Phase III results of GCAptAIN did not replicate the positive outcomes observed in the Phase II trial, we remain committed to continuing to drive scientific progress and deepening the understanding of immune-mediated diseases,” said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer, Novartis. “We are grateful to the patients, investigators, and teams who made this study possible and will continue focusing on addressing areas of unmet medical need.”\nNovartis will complete a full evaluation of the GCAptAIN data and share the results at a later date.\nLesen Sie auch Kassenschlager Keytruda KGV einstellig, 4 Prozent Dividende: Merck-Aktie zu günstig um wahr zu sein? gestern 20:45 Aktie taucht ab Milliardengrab: Supreme Court lässt Bayer-Aktionäre weiter hängen! 01.07.25, 08:44 Gewinner und Verlierer DAX-Halbjahresbilanz 2025 - Die 5 besten und schlechtesten DAX-Aktien 01.07.25, 07:15 China baut seine Avengers Mag 7 war gestern: Goldmänner wetten jetzt auf \"Prom 10\" – Xiaomi, BYD & Co! 29.06.25, 16:29 1 Kommentar About GCAptAIN trial\nThe GCAptAIN trial (NCT04930094) is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted across 27 countries, evaluating the efficacy and safety of Cosentyx in patients with giant cell arteritis (GCA). Patients were randomized into three treatment arms: Cosentyx 300 mg, Cosentyx 150 mg, or placebo, all in combination with a glucocorticoid (GC) taper regimen. The primary endpoint of the trial is to assess whether secukinumab 300 mg s.c. plus a 26-week GC taper is superior to placebo plus a 52-week GC taper in achieving sustained remission at Week 52 and the first secondary endpoint is the cumulative GC dose through Week 52 8 .\nSeite 1 von 5 Seite 2 ►\nDiskutieren Sie über die enthaltenen Werte",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "negative",
  "categories": [
    "Health",
    "Science and Technology"
  ],
  "topics": [
    "Health->medical condition",
    "Health->medical specialisation",
    "Health->health treatment and procedure",
    "Science and Technology->medical research",
    "Science and Technology->scientific publication",
    "Science and Technology->biotechnology"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": false,
  "webz_reporter": false,
  "external_links": [
    "https://www.sg-zertifikate.de",
    "https://www.sg-zertifikate.de/product-details/SX4MRB?utm_source=wallstreet-online&utm_medium=integration-news-chartanalysen&utm_content=produktdetailseite&utm_campaign=zertifikate-website",
    "https://www.sg-zertifikate.de/product-details/SU4JHN?utm_source=wallstreet-online&utm_medium=integration-news-chartanalysen&utm_content=produktdetailseite&utm_campaign=zertifikate-website",
    "https://www.sg-zertifikate.de/product-details/SX4MRB",
    "https://sg-zertifikate.de/product-details/SX4MRB?utm_source=wallstreet-online&utm_medium=integration-news-chartanalysen&utm_content=produktdetailseite&utm_campaign=zertifikate-website",
    "https://www.sg-zertifikate.de/product-details/SU4JHN",
    "https://sg-zertifikate.de/product-details/SU4JHN?utm_source=wallstreet-online&utm_medium=integration-news-chartanalysen&utm_content=produktdetailseite&utm_campaign=zertifikate-website",
    "https://sg-zertifikate.de"
  ],
  "entities": {
    "persons": [
      {
        "name": "Anzeige Handeln Sie Ihre Einsch",
        "sentiment": "none"
      }
    ],
    "locations": [],
    "organizations": [
      {
        "name": "Cosentyx",
        "sentiment": "none",
        "tickers": []
      }
    ]
  },
  "syndication": {
    "syndicated": false,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [],
    "bias": null
  },
  "rating": null,
  "crawled": "2025-07-03T09:02:36.936+03:00",
  "updated": "2025-07-03T09:06:55.954+03:00"
}